StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Merck (MRK) Confirms FDA Approved its ZERBAXA 3g Dose for Treatment of Adults with HABP/VABP
June 3, 2019 4:57 PM
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
FDA Approves Merck’s ZERBAXA® (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
June 3, 2019 4:55 PM
FDA approves Merck's (MRK) new treatment for hospital-acquired and ventilator-associated bacterial pneumonia
June 3, 2019 3:31 PM
